Literature DB >> 18771399

Shift-invariant adaptive double threading: learning MHC II-peptide binding.

Noah Zaitlen1, Manuel Reyes-Gomez, David Heckerman, Nebojsa Jojic.   

Abstract

The major histocompatibility complex (MHC) plays important roles in the workings of the human immune system. Specificity of MHC binding to peptide fragments from cellular and pathogens' proteins has been found to correlate with disease outcome and pathogen or cancer evolution. In this paper we propose a novel approach to predicting binding configurations and energies for MHC class II molecules, whose epitopes are generally predicted less well than the MHC I epitopes due in part to larger variation in bound peptide length. We treat the relative position of the peptide as a hidden variable, and model the ensemble of different binding configurations, rather than use a separate alignment procedure to narrow it down to one. Thus, our predictor infers a distribution over peptide positions from the MHC II and peptide sequences, and computes the total binding affinity. The training procedure iterates the predictions with re-estimation of the parameters of the binding groove model. For a given relative peptide position, any MHC class I prediction model can be used. Here we choose the physics based model of Jojic et al. (2006). We show that the parameters of the binding model can be learned efficiently from the training data and then used to estimate binding energies for previously untested peptides. Our technique performs on par with previous approaches to MHC II epitope prediction. Furthermore, our model choice allows generalization to new MHC class II alleles, which were not a part of the training set.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18771399     DOI: 10.1089/cmb.2007.0183

Source DB:  PubMed          Journal:  J Comput Biol        ISSN: 1066-5277            Impact factor:   1.479


  8 in total

Review 1.  MHC class II epitope predictive algorithms.

Authors:  Morten Nielsen; Ole Lund; Søren Buus; Claus Lundegaard
Journal:  Immunology       Date:  2010-04-12       Impact factor: 7.397

2.  Limitations of Ab initio predictions of peptide binding to MHC class II molecules.

Authors:  Hao Zhang; Peng Wang; Nikitas Papangelopoulos; Ying Xu; Alessandro Sette; Philip E Bourne; Ole Lund; Julia Ponomarenko; Morten Nielsen; Bjoern Peters
Journal:  PLoS One       Date:  2010-02-17       Impact factor: 3.240

3.  NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ.

Authors:  Edita Karosiene; Michael Rasmussen; Thomas Blicher; Ole Lund; Søren Buus; Morten Nielsen
Journal:  Immunogenetics       Date:  2013-07-31       Impact factor: 2.846

4.  NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure.

Authors:  Morten Nielsen; Sune Justesen; Ole Lund; Claus Lundegaard; Søren Buus
Journal:  Immunome Res       Date:  2010-11-13

5.  TEPITOPEpan: extending TEPITOPE for peptide binding prediction covering over 700 HLA-DR molecules.

Authors:  Lianming Zhang; Yiqing Chen; Hau-San Wong; Shuigeng Zhou; Hiroshi Mamitsuka; Shanfeng Zhu
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

6.  MHC2SKpan: a novel kernel based approach for pan-specific MHC class II peptide binding prediction.

Authors:  Linyuan Guo; Cheng Luo; Shanfeng Zhu
Journal:  BMC Genomics       Date:  2013-10-16       Impact factor: 3.969

7.  MHC2MIL: a novel multiple instance learning based method for MHC-II peptide binding prediction by considering peptide flanking region and residue positions.

Authors:  Yichang Xu; Cheng Luo; Mingjie Qian; Xiaodi Huang; Shanfeng Zhu
Journal:  BMC Genomics       Date:  2014-12-08       Impact factor: 3.969

8.  Trans-Allelic Model for Prediction of Peptide:MHC-II Interactions.

Authors:  Abdoelnaser M Degoot; Faraimunashe Chirove; Wilfred Ndifon
Journal:  Front Immunol       Date:  2018-06-20       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.